Table 4.

Quantitative analysis of the relative changes in mRNA expression levels of different GAGs synthesizing enzymes using qRT-PCR in placenta of pre-eclampsia affected women

	Gene	CTa	ΔCTb	ΔΔCTc	Expression relative to controld
Chondroitin 4-O-sulfotransferase 1 (C4ST)
Pre-eclampsia	GAPDH	16.54±0.38	5.25±0.61	1.35	0.39
	C4OS	21.79±0.24
Control	GAPDH	17.43±0.17	3.9±0.25
	C4OS	21.33±0.18
Chondroitin 6-O-sulfotransferase (C6ST)
Pre-eclampsia	GAPDH	16.54±0.38	7.913±0.45	2.9	0.134
	C6S	24.45±0.61
Control	GAPDH	17.43±0.17	5±0.6
	C6S	22.43±0.43
Dermatan/chondroitin sulfate 2-O-sulfotransferase (C2ST)
Pre-eclampsia	GAPDH	16.54±0.38	8.45±0.64	2.3	0.2
	CS2S	24.99±0.49
Control	GAPDH	17.43±0.17	6.15±0.70
	CS2S	23.58±0.53
Heparan N-deacetylase/N-sulfotransferase-1 (NDST-1)
Pre-eclampsia	GAPDH	16.54±0.38	3.85±0.29	-0.167	1.123
	HDS-1	20.53±0.48
Control	GAPDH	17.43±0.17	4.02±1.03
	HDS-1	21.45±0.86
Heparan sulfate 6-O-sulfotransferase 1 (HS6ST)
Pre-eclampsia	GAPDH	16.54±0.38	7.21±1.29	1.78	0.29
	HS6S	23.75±1.12
Control	GAPDH	17.43±0.17	5.43±1.02
	HS6S	22.87±0.85

^aThe average of the C_T data for each sample

^bThe ΔC_T value is calculated by the subtraction of the GAPDH C_T from each sample C_T

^cThe ΔΔC_T value is calculated by subtraction of the control ΔC_T from each pre-eclampsia sample ΔC_T

^dThe expression relative to control is calculated using the equation 2^{−ΔΔ C_T}